Edition:
United States

Profile: Teva Pharmaceutical Industries Ltd (TEVA.K)

TEVA.K on New York Consolidated

36.53USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$36.53
Open
--
Day's High
--
Day's Low
--
Volume
17,477
Avg. Vol
8,267,078
52-wk High
$66.55
52-wk Low
$36.41

Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company has a global portfolio of approximately 1,000 molecules.

Generic Medicines

The Company develops, manufactures and sells generic pharmaceutical products in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Company offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances in both parenteral and solid dosage forms. The Company produces approximately 300 active pharmaceutical ingredients (APIs) for its own use and for sale to third parties in various therapeutic areas. It markets approximately 370 generic products in over 1,100 dosage strengths and packaging sizes, including oral, injectable and inhaled products.

Specialty Medicines

The Company's specialty medicines business is focused on delivering solutions to patients and providers through medicines, devices and services in key regions and markets around the world. The Company's specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines. The Company has specialty products in oncology, women's health and selected other areas. The Company's CNS portfolio includes Copaxone for the treatment of relapsing forms of multiple sclerosis, Azilect (rasagiline tablets) for the treatment of the symptoms of Parkinson's disease and Nuvigil (armodafinil) for the treatment of sleep disorders, as well as several therapies for the treatment of pain care, including Fentora (fentanyl buccal tablet), Amrix and Zecuity. Its product, Copaxone, contains glatiramer acetate injection in 20 milligram/milliliters and 40 milligram/milliliters strengths. Its CNS portfolio also includes Actiq (fentanyl oral transmucosal lozenge) for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer.

The Company's product candidate, SD-809 (deutetrabenazine), is a deuterated form of a small molecule inhibitor of vesicular monoamine 2 transporter (VMAT2) that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. SD-809 is in clinical development for the treatment of Tardive dyskinesia and Tourette syndrome. Laquinimod is a once-daily, orally administered immunomodulatory compound. The Company is developing Laquinimod for treatment of relapsing-remitting and progressive forms of multiple sclerosis. Pridopidine is an oral small molecule dopamine stabilizer being developed for the symptomatic treatment of motor disorders, including Huntington disease. The Company is conducting Phase II clinical study to evaluate the safety and efficacy of pridopidine in patients with Huntington disease.

The Company's clinical pipeline of migraine and pain products includes Vantrela ER, TV-46763, TV-46139, TEV-48125 and TV-45070. Vantrela ER (CEP-33237 Extended Release Hydrocodone) is its formulation of hydrocodone, an opioid analgesic, utilizing its OraGuard technology. TV-46763 is in Phase III development for safety and efficacy evaluation. TV-46139 is in early clinical development. TEV-48125 is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). TV-45070 Topical is a small molecule intended to treat pain locally.

The Company's product, ProAir hydrofluoroalkane (HFA) inhalation aerosol with dose counter (albuterol sulfate), is indicated in patients, approximately four years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. QVAR (beclomethasone dipropionate HFA) is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients approximately five years of age or older. QVAR is also indicated for asthma patients requiring systemic corticosteroid administration. Duoresp Spiromax (budesonide/formoterol) is a combination of an inhaled corticosteroid and a long acting beta-agonist bronchodilator for treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults. Its respiratory portfolio also includes Qnasl Nasal Aerosol.

The Company's delivery systems include breath-actuated inhaler (BAI) called Easi-Breathe, Spiromax/RespiClick and Tidal Inhaler. Its ProAir RespiClick US is a dry-powder inhaler formulation of albuterol in its multi-dose powder inhaler device. Reslizumab is an investigational humanized monoclonal antibody (MAb) against interleukin-5 (IL-5). QVAR BAI US (beclomethasone) is an oral aerosol corticosteroid in development for the treatment of asthma for ages over four years and older. Fluticasone Propionate MDPI US is a formulation of long acting corticosteroid (LCS) using its multi-dose powder inhaler device. TV-44664 (Fluticasone Salmeterol DPI) is a long acting beta2-agonist and an inhaled corticosteroid combined for the treatment of asthma in patients over four years of age and older. TV-44664 is in phase I clinical development. TV-44649 (Budesonide Formoterol HFA MDI) is a long acting beta2-agonist and an inhaled corticosteroid combined for the treatment of asthma in patients over 12 years of age and older. TV-44649 is in phase I clinical development. Its respiratory pipeline also include Fluticasone Salmeterol (MDI) EU, Fluticasone Salmeterol MDPI US and Fluticasone Salmeterol Spiromax EU.

The Company's oncology portfolio includes Treanda, Granix,Trisenox and Synribo in the United States and Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim and Trisenox outside the United States. The Company's product, Treanda (bendamustine hydrochloride injection), is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin's lymphoma (NHL). Bendeka (bendamustine hydrochloride) injection is indicated for the treatment of patients with CLL and patients with indolent B-cell NHL. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel), Zoely, Seasonique and Ovaleap, along with a number of other products marketed in various countries. Plan B One-Step OTC/Rx (levonorgestrel) is an emergency oral contraceptive. ParaGard T380 A (intrauterine copper contraceptive) is a non-hormonal intrauterine contraceptive. Its product candidate, CEP-41750 (Mesenchymal Precursor Cell, Revascor) consists of human stem cells, the immature cells. TEV-90110, TEV-90111, TEV-90112 and TEV-90113 are fixed dose combination products containing antiretrovirals for the treatment of human immunodeficiency virus (HIV), all of which are in Phase I clinical development.

The Company competes with Biogen, Novartis, Genzyme, GlaxoSmithKline, Merck, Sunovion, AstraZeneca, Chiesi and Bayer.

Company Address

Teva Pharmaceutical Industries Ltd

5 Basel St.,
P.O. Box 3190
PETAH TIKVA     49131
P: +9723.9267267
F: +9723.9234050

Company Web Links